Quanterix Stock

Quanterix Corporation (Quanterix) operates as a life sciences company.

The company engages in developing next-generation, ultra-sensitive digital immunoassay platforms that advance life sciences research and diagnostics. Its platforms are based on its proprietary digital ‘Simoa’ detection technology. The company’s Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allow researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations. These capabilities provide the company’s customers with insight into the role of protein biomarkers in human health that has not been possible with other existing technologies and enable researchers to unlock unique insights into the continuum between health and disease.

The company’s Simoa platforms have achieved significant scientific validation and commercial adoption. Simoa technology has been cited in over 2,000 scientific publications in areas of high unmet medical need and research interest, such as neurology, oncology, cardiology, infectious disease, and inflammation. The company’s growing customer base is consisted of over 1,300 customers across its end markets.

Products and Services

The company’s proprietary Simoa technology is based on traditional ELISA technology. The company’s Simoa bead-based platform differs, however, from conventional ELISA in its ability to trap single molecules in tiny microwells, 40 trillionths of a milliliter, that are 2.5 billion times smaller than traditional ELISA wells, allowing for an analysis and digital readout of each individual molecule, which is not possible with conventional ELISA technology. Leveraging the company’s proprietary sophisticated Simoa image analysis and data analysis algorithms, the company has also developed a planar array technology to provide sensitivity similar to that found in the company’s Simoa bead-based platform. The company offers the following three Simoa instruments, which are among the most sensitive multiplex protein detection platforms commercially available today:

HD-X: The company commercially launched its HD-X instrument in the second half of 2019. The HD-X is an upgraded version of the Simoa HD-1 (its first Simoa instrument, which was launched in January 2014) that was designed to deliver significant productivity and operational efficiency improvements, as well as greater user flexibility. The HD-X is based on the company’s bead-based technology, and assays run on the HD-X are fully automated.

SR-X: The company commercially launched its SR-X instrument in December 2017. The SR-X utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a lower price point, more flexible assay preparation, and a wider range of potential applications.

SP-X: The company commercially launched its SP-X instrument in April 2019. The SP-X is based on the company’s Simoa planar array technology, which allows for significantly greater multiplexing capabilities, and is ideal for oncology and immunology applications.

The current menu of approximately 36 analyte-specific single-plex and multi-plex bead-based assay kits includes assays for biomarkers in the areas of neurology, infectious disease, immunology, oncology and cardiology for both human and mouse samples. The current menu of Simoa planar array reagent kits includes approximately 115 biomarkers ranging from 1-10 analytes per assay in the areas of immunology and oncology research. In addition, both the bead-based platform and the planar array platform allow ease and flexibility in assay design, enabling the company’s customers to develop their own in-house assays, called ‘homebrew’ assays.

The company also provides contract research services for customers through its CLIA-certified Accelerator Laboratory. The Accelerator Laboratory provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development. As of December 31, 2022, the company completed over 1,900 projects for more than 400 customers from all over the world using the company’s Simoa platforms. The company has recently begun offering laboratory developed tests (LDTs) through the Accelerator Laboratory. LDTs are diagnostic tests that are developed, validated and performed by a single laboratory. In July 2022, the company launched an LDT to quantitatively measure phospho-Tau 181 (pTau-181) in plasma as an aid in diagnostic evaluation of Alzheimer’s disease. In January 2023, the company launched an LDT to quantitatively measure neurofilament light chain (NfL) in serum as an aid in the evaluation of individuals for possible neurodegenerative conditions or other causes of neuronal or central nervous system damage.

In August 2019, the company acquired UmanDiagnostics AB (Uman), a company located in Umeå, Sweden, that commercializes proprietary NfL antibodies and NfL ELISA kits. Uman’s NfL antibodies are widely recognized by researchers and biopharmaceutical and diagnostics companies world-wide as the premier solution for the detection of NfL to advance the development of therapeutics and diagnostics for certain neurodegenerative conditions. Since the company commercially launched the first assay that could reliably measure NfL in blood using Uman’s antibodies and the company’s Simoa technology in 2017, NfL has seen dramatic growth as a neurological biomarker. The Uman acquisition secured the NfL antibody supply critical to the company’s industry-leading ultrasensitive Simoa NfL assays and services and provides the company with additional revenue via the sale of the NfL antibodies and NfL ELISA kits.

The company sells its instruments, consumables and services to the life science, pharmaceutical and diagnostics industries through a direct sales force and support organizations in North America and Europe; and through distributors or sales agents in select markets. In addition, the company sells Uman’s NfL antibodies and NfL ELISA kits directly and in conjunction with a distributor worldwide. The company has an extensive base of customers in world class academic and governmental research institutions, as well as pharmaceutical, biotechnology and contract research companies, using the company’s technology to gather information to better understand human health.

Strategy

The company’s strategies are to focus on the highly attractive, expanding market for protein detection and analysis; continue to drive adoption of its Simoa technology in the life science research/pharma market; expand its presence in the diagnostics market; leverage the growing importance of neurological biomarkers to advance the development of therapeutics and diagnostics for neurodegenerative conditions; and expand further into indications beyond neurology.

Key Focus Areas

The company has focused the application of its Simoa technology on areas of high growth and high unmet need and where existing platforms have significant shortcomings that the company’s technology addresses, including neurology and oncology, as well as cardiology, infectious disease and inflammation.

Products and Services

The company’s Quanterix commercial portfolio includes research use only (RUO) instruments, assay kits and other consumables, and contract research services offered through the company’s Accelerator Laboratory.

Instruments and Consumables

HD-X

The company commercially launched its HD-X instrument in the second half of 2019. The HD-X is an upgraded version of the Simoa HD-1, the company’s very first instrument, which was launched in January 2014. The HD-X was designed to deliver significant productivity and operational efficiency improvements, as well as greater user flexibility. The HD-X uses the company’s Simoa bead-based technology and is the most sensitive automated multiplex protein detection platform commercially available. Assays for the HD-X are fully automated (i.e., from sample in to result out), and results for up to 66 samples are available in approximately one hour. Samples can be input into the instrument via 96-well microtiter plates or sample tubes where the system can multiplex and process tests in a variety of assay protocol configurations.

Specialized software controls the Simoa instrumentation, analyzes the digital images produced, and provides customers with detailed analysis of their samples, such as the concentration of multiple biological molecules. The HD-X software automates the processes for running the instrument and analyzing data from the user-defined protocols. Proprietary image analysis software is embedded in the system, which converts the raw images into signals for each biological molecule being analyzed within a sample. Data reduction software automatically converts those signals to concentrations for the different biological molecules.

SR-X

The company commercially launched the SR-X instrument in the fourth quarter of 2017. The SR-X utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a lower price point designed to address the needs of researchers who value the ultra-sensitive detection capabilities enabled by Simoa.

In contrast to the fully automated workflow of the HD-X, the assay incubation and washing steps for the SR-X are performed outside of the instruments using conventional liquid handling methods. The offline sample prep provides additional flexibility to enable researchers to apply Simoa detection in an expanded range of applications, including direct detection of nucleic acids. The SR-X system automates the steps loading Simoa beads onto Simoa disks with subsequent imaging, detection and data reduction. Processing time for imaging a 96 well plate is approximately 2.5 hours.

SP-X

The company commercially launched the SP-X instrument in April 2019. The SP-X uses the Simoa planar array technology developed initially by Aushon Biosystems (Aushon), which the company acquired in 2018, for multiplex chemiluminescent immunoassay measurement, which the company refined by leveraging its proprietary sophisticated Simoa image analysis and data analysis algorithms to provide sensitivity similar to that found in the company’s Simoa bead-based platform. The Simoa planar array technology utilizes a 96-well microtiter plate with up to 10 different assay measurements performed in each well of the plate from as little as 12.5 microliters of sample.

Similar to the SR-X, the assay prep workflow utilized for the SP-X involves assay incubation and washing steps performed outside of the instrument using the same conventional liquid handling methods as the SR-X. The SP-X instrument automates the imaging, detection and data reduction process. Processing time for imaging a 96 well plate is less than five minutes.

Simoa Assays and Consumables

Recurring revenue is derived through the sale of consumables used to run assays on the company’s instruments and from its growing menu of Simoa digital biomarker assays. The current menu of approximately 36 analyte-specific single-plex and multi-plex assay kits for the company’s bead-based instruments includes assays for biomarkers in the areas of neurology, infectious disease, immunology and oncology for both human and mouse samples. The current menu of assay kits for the planar array instrument includes approximately 115 biomarkers ranging from 1-10 analytes per assay in the areas of immunology and oncology research.

In addition to these assays the company have developed, both of the Simoa platforms allow ease and flexibility in assay design, enabling the company’s customers to develop their own proprietary in-house assays, called homebrew assays, using the company’s homebrew assay kits. These kits include all components required for customers to run tests using their own antibodies. The company’s consumables portfolio for its bead-based platform also includes the company’s proprietary Simoa disks that are unique to its bead-based platform, as well as cuvettes and disposable tips.

The company has staffed its assay development and manufacturing teams to do the upfront work of antibody sourcing, assay development and optimization, sample testing and validation, transfer to manufacturing and final documentation.

The company outsources some of its assay development activities to other antibody and/or assay development providers and expects to continue to do so to achieve the company’s aggressive menu expansion goals.

NfL Antibodies and NfL ELISA Kits

Uman is the company’s wholly owned subsidiary that supplies NfL antibodies and ELISA kits for NfL detection. Uman’s NfL antibodies are widely recognized by researchers and biopharmaceutical and diagnostics companies worldwide as the premier solution for the detection of NfL to advance the development of therapeutics and diagnostics for neurodegenerative conditions. Through Uman, the company sells proprietary NfL capture and detection antibodies, as well as two NfL ELISA kits for CSF, one of which is CE-certified in Europe and one RUO NfL ELISA kit for serum.

Services

Through the company’s Accelerator Laboratory, which includes a CLIA-certified laboratory, the company provides customers a contract research option. Researchers, academics and principal investigators can work with the company’s scientists to test specimens with existing Simoa assays, or prototype, develop and optimize new assays. The Accelerator Laboratory supports multiple projects and services, including:

Sample Testing: Utilizing commercially available Simoa kits, the company has run large studies for customers with thousands of specimens and small experiments with just a few samples. The sample protocol can be tailored precisely to the customer’s needs and even large studies can be run quickly. The company has extensive experience testing many different sample types where biomarkers may be present at very low levels.

Homebrew Assay Development: Utilizing proprietary or commercially available reagents in combination with the company’s Homebrew Assay Development Kit, the company can rapidly develop a prototype assay exhibiting improved sensitivity compared to traditional ELISA. The Accelerator Laboratory can also be used to screen reagents to identify the optimal assay format or expand prototype efforts for further assay optimization or validation to ultimately deliver the highest level of performance.

Custom Development: After identifying the optimal assay and conditions, the Accelerator Laboratory can be used to generate qualified bulk reagents or custom assay kits, providing customer access to validated kits for assays not yet commercially available on the Simoa platform.

LDT Testing. The company has recently begun offering LDT testing through the company’s CLIA-certified laboratory. In July 2022, the company launched an LDT to quantitatively measure pTau-181 in plasma as an aid in diagnostic evaluation of Alzheimer’s disease, and in January 2023, the company launched an LDT to quantitatively measure NfL in serum as an aid in the evaluation of individuals for possible neurodegenerative conditions or other causes of neuronal or central nervous system damage.

As of December 31, 2022, the company completed over 1,900 projects for more than 400 customers from all over the world using the company’s Simoa platforms. In addition to being an important source of revenue, the company has found the Accelerator Laboratory to be a catalyst for placing additional instruments, as a number of customers for whom the company has provided contract research services have subsequently purchased an instrument from the company.

The company also generates revenues through extended-warranty and service contracts for the company’s installed base of instruments.

Research and Development

The company’s research and development expenses were $25.9 million for the year ended December 31, 2022.

Service Marks, Trademarks and Trade Names

‘Quanterix,’ ‘Simoa,’ ‘Simoa HD-X,’ ‘Simoa HD-1,’ ‘SR-X,’ ‘SP-X’, ‘HD-X’, ‘NF-light’ and the company’s logo are the company’s trademarks.

Sales and Marketing

The company distributes its Simoa instruments and consumables via direct field sales and support organizations located in North America and Europe and through a combination of the company’s own sales force and third-party distributors in additional major markets, including Australia, Brazil, China, the Czech Republic, India, Hong Kong, Israel, Japan, New Zealand, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Taiwan, and the U.A.E. In addition, the company sells Uman’s NfL antibodies and NfL ELISA kits directly and in conjunction with a distributor worldwide. The company’s domestic and international sales force informs its customers of product offerings, new product and new assay introductions, and technological advances in Simoa systems, workflows, and notable research being performed by the company’s customers or the company. As the company’s primary point of contact in the marketplace, the company’s sales force focuses on delivering a consistent marketing message and high level of customer service, while also attempting to help the company better understand evolving market and customer needs.

As of December 31, 2022, the company had 125 full-time employees in sales, sales support and marketing, including technical field application scientists and field service personnel. This staff is primarily located in North America and Europe. The company expects it will expand its sales, support, and marketing efforts in the future by expanding the company’s direct footprint in Europe, as well as developing a comprehensive distribution and support network in China where significant new market opportunities exist. Additionally, there is significant opportunity in other Asia-Pacific region countries, such as South Korea and Australia, as well as in South America. The company is expanding into these regions via initial penetration with distributors and then subsequent support with Quanterix-employed sales and support personnel.

The company’s sales and marketing efforts are targeted at key opinion leaders, laboratory directors and principal investigators at leading biotechnology and pharmaceutical companies and governmental research institutions.

In addition to the company’s selling activities, the company aligns with key opinion leaders at leading institutions and clinical research laboratories to help increase scientific and commercial awareness of the company’s technologies, demonstrate the benefits relative to existing technologies and accelerate adoption.

Manufacturing and Supply

Instruments

The HD-X instrument is manufactured by STRATEC Biomedical AG (STRATEC), based in Birkenfeld, Germany, and is manufactured and shipped from their Birkenfeld and Beringen, Switzerland facilities. The SR-X is manufactured by Paramit Corporation (Paramit), based in Morgan Hill, California, and is shipped to the company’s global customers by Paramit.

Consumables

Simoa disks for the company’s bead-based platform are supplied through a single source supplier pursuant to a long-term supply agreement with STRATEC Consumables, a subsidiary of STRATEC Biomedical.

The company’s cuvettes for its bead-based platform are single sourced through STRATEC Biomedical, and the disposable tips used in the company’s bead-based platform are commercially available.

NfL antibodies and NfL ELISA Kits

All components in Uman’s NfL ELISA kits are manufactured in-house at Uman from starting materials sourced from suppliers that have been evaluated and approved. Uman has entered into supply agreements with critical suppliers.

Key Agreements

Development Agreement and Supply Agreement with STRATEC

In August 2011, the company entered into a Strategic Development Services and Equity Participation Agreement with STRATEC, pursuant to which STRATEC undertook the development of the Simoa HD instrument. In September 2011, the company also entered into a Supply and Manufacturing Agreement with STRATEC (the STRATEC Supply Agreement), pursuant to which STRATEC agreed to supply HD instruments to the company, and it agreed to procure those instruments exclusively from STRATEC, subject to STRATEC’s ability to supply the instruments.

Paramit Manufacturing Services Agreement

In November 2016, the company entered into a Manufacturing Services Agreement (the Paramit Agreement) with Paramit. Under the terms of the Paramit Agreement, the company engaged Paramit to produce and test the company’s SR-X instrument on an as-ordered basis. The company also engaged Paramit to supply spare parts for the SR-X instrument.

Competition

The company competes with both established and development-stage life science companies that design, manufacture and market instruments for proteomics discovery and clinical research applications. For example, companies, such as Bio-Techne, Luminex, MesoScale Discovery, Gyros, O-Link, SEER, Somalogic, MilliporeSigma, Bio-Rad Laboratories, Thermo Fisher Scientific, and others, have products for protein measurements in biofluids that compete in certain segments of the market in which the company sells its products.

The company’s Accelerator Laboratory competes with other research laboratories, such as Covance, Q2 Solutions, Rules Based Medicine, Monogram Biosciences, PPD Laboratories, and others, some of whom are customers of the company.

Intellectual Property

Simoa and Related Technology

As of March 1, 2023, the company had exclusively licensed 17 patents and two patent applications from Tufts. These patents and patent applications include eight issued U.S. patents and two pending U.S. patent applications, three granted European patents, three granted Japanese patents, two granted Canadian patents and one granted Australian patent.

A first patent family licensed from Tufts is directed to methods for detecting single molecules. This patent family includes seven granted U.S. patents, one pending U.S. patent application, three granted European patents (each nationalized and active in seven or eight countries), three granted Japanese patents, two granted Canadian patents and one granted Australian patent. The standard patent expiration date for U.S. patents in this family is February 16, 2027, and for the non-U.S. patents is February 20, 2027 or August 30, 2027.

A second patent family licensed from Tufts is directed to methods for detecting the presence of target analytes in multiple samples. This patent family includes one granted U.S. patent. The standard patent expiration date for the U.S. patent in this family is August 22, 2025.

A third patent family licensed from Tufts is directed to methods for detecting short nucleic acids. This patent family includes one pending U.S. patent application. The standard patent expiration date for any U.S. patents that may issue in this family is May 29, 2039.

As of March 1, 2023, the company owned 29 issued U.S. patents and 17 pending U.S. patent applications, eight granted European patents and three pending European patent applications, six granted Japanese patents and one pending Japanese patent application, four granted Chinese patents and two pending Chinese patent application, four granted Canadian patents and one pending Canadian patent application, and one registered Hong Kong patent application.

A first patent family owned by the company is directed to methods for determining a measure of the concentration of analyte molecules or particles in a fluid sample, and in particular to methods for analyte capture on beads, including multiplexing. This patent family includes four granted U.S. patents and two pending U.S. patent applications, three granted European patents (nationalized and active in eight countries) and one pending European application, two granted Japanese patents, two granted Chinese patents, and one granted Canadian patent. The standard patent expiration date for the U.S. patents in this family is March 24, 2030, and for the non-U.S. patents is March 1, 2031.

A second patent family owned by the company is directed to methods and systems for determining a measure of the concentration of analyte molecules or particles in a fluid sample, and in particular to methods or systems for determining concentration based on either counting or measured intensity (extending the dynamic range). This patent family includes five granted U.S. patents and one pending U.S. patent application, one granted European patent (nationalized and active in seven countries), two granted Japanese patents, one granted Chinese patent, and one granted Canadian patent. The standard patent expiration date for the U.S. patents in this family is March 24, 2030, and for the non-U.S. patents is March 1, 2031.

A third patent family owned by the company is directed to methods for determining a measure of the concentration of analyte molecules or particles in a fluid sample, and in particular to methods for analyte capture on beads with or without dissociation. This patent family includes two granted U.S. patents. The standard patent expiration date for the U.S. patents in this family is September 28, 2028.

A fourth patent family owned by the company is directed to methods for determining a measure of the concentration of analyte molecules or particles in a fluid sample, and in particular to methods for determining concentration using multiple binding ligands for the same analyte molecule. This patent family includes one granted U.S. patent. The standard patent expiration date for the U.S. patent in this family is March 24, 2030.

A fifth patent family owned by the company is directed to instruments and consumables. This patent family includes two granted U.S. patents and one pending U.S. patent application, one granted European patent (nationalized and active in eleven countries) and one pending European patent application, two granted Japanese patents, one granted Chinese patent and one pending Chinese patent applications, one registered Hong Kong patent application, and one granted Canadian patent. The standard patent expiration date for the U.S. patents in this family is February 25, 2031, and for any non-U.S. patents is January 27, 2032.

A sixth patent family owned by the company is directed to methods and materials for covalently associating a molecular species with a surface. This patent family includes one pending U.S. patent application. The standard patent expiration date for any U.S. patents that may issue from this family is May 9, 2034.

A seventh patent family owned by the company is directed to methods for improving the accuracy of capture based assays. This patent family includes one pending U.S. patent application. The standard patent expiration date for any U.S. patents that may issue from this family is January 13, 2036.

An eighth patent family owned by the company is directed to methods and systems for reducing and/or preventing signal decay. This patent family includes one pending U.S. patent application. The standard patent expiration date for any U.S. patents that may issue from this family is September 20, 2038.

A ninth patent family owned by the company is directed to methods and systems for highly sensitive assays, including methods and systems for improving capture object loading efficiency and/or use of low numbers of capture objects in assays. This patent family includes one pending U.S. patent application, one pending European patent application, one pending Japanese patent application, one pending Chinese patent application, and one pending Canadian patent application. The standard patent expiration date for any patents that may issue from this family is April 14, 2041.

In addition to the nine patent families described above, the company owns or co-owns nine additional patent families directed to the measurement of particular types of analytes, including ß-amyloid peptide, tau protein, toxin B of C. difficile, neurofilament light, glial fibrillary acidic protein, ubiquitin carboxyl-terminal hydrolase L1, antigens from infectious organisms, such as viruses (e.g., coronaviruses), and DNA or RNA molecules. Among the granted patents and pending patent applications in these nine families are two granted U.S. patents directed to methods for determining treatment protocols and/or a prognosis of a patient’s recovery from a brain injury based on measurements of tau protein in blood and one granted U.S. patent and one granted European patent (nationalized and active in three countries) directed to detection of C. difficile. Any patents that may issue from these patent applications would have standard expiration dates between 2032 and 2041.

With the acquisition of Aushon in January 2018, the company acquired their patent portfolio for its planar array technology. As of March 1, 2023, the acquired patent portfolio includes at least ten issued U.S. patents and one pending U.S. patent application, one granted Canadian patent, and two granted European patents (nationalized and active in eight countries).

The company has licensed additional patents and patent applications from third parties. These include a portfolio of patent filings the company licensed from Harvard University directed to additional single molecule assay technologies originated in the laboratory of Professor David Walt, who is the founder of Quanterix and a current member of the company’s Board of Directors.

A first patent family exclusively licensed by the company from Harvard University is directed to assays that provide digital measurement methods to detect proteins and other biomolecules, e.g., at low- to mid-attomolar concentrations. This patent family includes one pending International Patent Application. The standard patent expiration date for any patents that may issue from this family is June 22, 2041.

A second patent family exclusively licensed by the company from Harvard University is directed to single molecule assays for ultrasensitive detection of analytes. The standard patent expiration date for any patents that may issue from this family will be in 2042.

A third patent family exclusively licensed by the company from Harvard University is directed to high-sensitivity methods for detection and quantification of target analytes in liquid samples (e.g., biological or environmental samples). The standard patent expiration date for any patents that may issue from this family is August 15, 2039.

A fourth patent family non-exclusively licensed by the company from Harvard University is directed to methods and compositions to detect Mycobacterium tuberculosis antigens, e.g., lipoarabinomannan (LAM) and/or Ag85B (Rv1886c), in a sample (e.g., a human urine sample) for diagnosis of tuberculosis. The standard patent expiration date for any patents that may issue from this family is December 17, 2040.

License Agreement with Tufts University

In June 2007, as amended in April 2013, August 2017, and September 2020, the company entered into a license agreement with Tufts, pursuant to which the company obtained an exclusive, worldwide license to research, develop, commercialize, use, make, or have made, import or have imported, distribute or have distributed, offer or have offered, and sell or have sold products and services covered by patent rights to the Simoa bead-based technology owned by Tufts, as well as a non-exclusive license to related know-how. The rights licensed to the company is for all fields of use and are sublicensable for a fee.

Government Regulation

The majority of the company’s products are intended for research use only (RUO) applications, although the company’s customers may use the company’s products to develop their own products that are subject to regulation by the FDA or the Center for Medicare & Medicaid Services (CMS).

The company owns and operates a CLIA-certified laboratory. When the company performs clinical diagnostic testing, the company is subject to the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as well as additional federal and state laws that impose a variety of fraud and abuse prohibitions on healthcare providers, including clinical laboratories.

The CE registration for the Nf-L ELISA assay kit of the company’s subsidiary Uman was approved in March 2014 under the IVD Directive.

The company is subject to EPA and state requirements relating to the management and disposal of hazardous waste, and state requirements relating to the disposal of regulated medical waste.

History

The company was founded in 2007. It was incorporated under the laws of the state of Delaware in April 2007. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007.